Disconnect between triglyceride reduction and cardiovascular outcomes: lessons from the PROMINENT and CLEAR Outcomes trials

Tokgozoglu L., Pirillo A., Catapano A. L.

EUROPEAN HEART JOURNAL, no.27, pp.2377-2379, 2023 (SCI-Expanded, Scopus) identifier identifier

  • Publication Type: Article / Editorial Material
  • Publication Date: 2023
  • Doi Number: 10.1093/eurheartj/ehad485
  • Journal Name: EUROPEAN HEART JOURNAL
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.2377-2379
  • Hacettepe University Affiliated: Yes

Abstract

TG-lowering treatments and atherosclerotic CV disease risk. A TG-lowering approach that results in TG lowering with no effect on apoB levels provides no clinical benefit; indeed, CV risk reduction is achievable when TG-lowering is accompanied by a reduction in apoB levels. TG: triglyceride; CE: cholesteryl ester; apoB: apolipoprotein B; CV: cardiovascular.